By Women’s HealthX

As healthcare organisations navigate tightening compliance mandates, evolving reimbursement frameworks, and shifting health economics, the single most critical asset for leadership is operational visibility into what their industry counterparts are executing right now.

Ahead of the Women’s HealthX marketplace in Boston this December, a cross-functional steering committee of health plans, hospital networks, biopharma innovators, and enterprise employers has launched the definitive 2026 U.S. Health Infrastructure Survey.

The objective of this brief, multi-state index is to bypass abstract market fluff and map out exactly how the country’s elite healthcare stakeholders are practically structuring their 2027 budgets, clinical protocols, and technology procurement guidelines.

Some of the questions we are asking:

• Health Plans & Payers “What is the biggest operational barrier to expanding women’s health coverage?”
• Health Systems & Providers “What is the biggest women’s health priority for health systems over the next 24 months?”
• Pharma & Life Sciences “What is the biggest commercial hurdle facing women’s health innovation?”
• Employers & Benefits Leaders “Which women’s health challenge creates the greatest workforce impact?”

By contributing just 60 seconds of your operational insight to the index, you will ensure your specific sector’s parameters are accurately represented.

In return for your participation, you will secure a priority, pre-ordered copy of the completed 30-page intelligence report when the final data drops this September!

See where your direct peer groups are drawing their line in the sand for the upcoming fiscal year.

Contribute 60 seconds and pre-order your national benchmark report

Women’s HealthX 2026 | From Rhetoric to Results

Encore Boston Harbor | December 3-4 2026

Bypass abstract market rhetoric to evaluate real-world health economics, regulatory compliance mandates, and care delivery systems.

Join the region’s foremost health plan medical directors, hospital COOs, biopharma innovators, and enterprise benefits buyers anchoring our 2026 tracks.

Review full agenda

Meet confirmed speakers

Secure your pass

Early bird pricing for Women’s Health Week Europe 2026 ends this Friday, and the room is already looking like one that you won’t want to miss.

A snapshot of organisations already registered includes Google, Merck, LSEG, Boots, Novo Nordisk, the Gates Foundation, MIT, HSBC, UCL, NHS England, MHRA, NICE, NIHR, British Business Bank, TELUS Global Ventures, Weber Shandwick, Verdane, Antler, Thena Capital, Calm/Storm Ventures, and a growing list of the most promising startups currently operating in the women’s health space.

700+ decision-makers, 2 days at The Emirates Stadium. Secure your place before prices increase.

What’s on the programme

For the first time, WHW Europe runs across two dedicated stages. The Global Stage covers the macro forces shaping the sector: funding trends, AI, the gender data gap, wearable technology, and European policy. The Scale Stage focuses on execution: regulatory approval pathways, building the evidence stack that wins payers, surviving the valley of death, and positioning for acquisition.

Confirmed speakers include Alison Cave (Chief Safety Officer, MHRA), Emily Darlington MP, Frida Polli (MIT), Nichole Young-Lin (Google), Merete Clausen (EIF), Kerry Buckley (Boots), Tim Davis (LSEG), Henriette Hessen (Verdane), Michael Lewis (NIHR), and Dr. Henrietta Hughes (Patient Safety Commissioner), among many others.

View the full speaker lineup.

Early bird pricing ends this Friday

Tickets are currently available at early bird rates, with savings of up to £500 off standard pricing.

To secure your spot where women’s health comes to scale, book now.

Femtech World explores the latest business and investment developments in the world of women’s health.

Funding supports US launch of world’s first AI-powered, automated IVF lab

Conceivable Life Sciences has raised US$50m to accelerate the development and commercialisation of the world’s first AI-powered automated IVF laboratory.

The funding will help to make the therapy more accessible, scalable and effective at delivering improved pregnancy results.

The Series A round brings Conceivable’s total funding to US$70m, including the company’s US$20m seed round, which closed in December 2022.

AURA utilises robotic precision and AI algorithms to remove variability and standardise more than 200 steps with the aim to deliver consistently successful IVF outcomes.

Conceivable is in active clinical operations and currently conducting a 100-patient pilot study.

The Series A funding will support Conceivable Life Sciences’s US debut next year, expanding its partnerships with fertility networks in 2026, marking the US commercial launch of the world’s first automated IVF lab.

“The fertility industry stands at a critical inflection point where breakthrough innovation will fundamentally expand access to care,” said Alex Christ, general partner at Advance Venture Partners.

“We saw a fragmented landscape of companies building low impact, point solutions for individual IVF processes, but only Conceivable tackling the full end-to-end approach to IVF that truly pushes the industry forward.

“By integrating these complex steps in one system, they’ve revolutionised the IVF lab with technology, engineering and biology at the core.

“Conceivable’s technology will enable the entire sector to deliver fertility care that’s more consistent, scalable, and, most importantly, within reach for the families who need it most.”

Truelli to advance R&D for world’s first menstrual pad with a built-in screening technology

Health tech startup Truelli is to advance its research and development on the world’s first menstrual pad that has a built-in screening technology designed to transform a period into a health checkpoint.

The company is developing a smart pad that analyses menstrual blood; an information-rich yet historically overlooked biomarker.

The technology is designed to routinely assess four key health indicators in women including nutrient levels, hormonal fluctuations, metabolic function and sexual health.

Results are delivered through a mobile application that syncs relevant data and provides actionable insights.

While innovation in women’s health is progressing, its impact is constrained by the lack of physiologically-relevant and robust R&D.

Without sustained investment that enriches our understanding of female-specific biology, real-world application of these innovations is fruitless.” said Dr. Saba Alzabin, Truelli co-founder and CSO.

“At Truelli, we’re transforming overlooked biological signals within the female cycle into tools that can support her healthspan.

“This has far-reaching potential in geographies where systemic and cultural barriers limit care for women and girls.”

NIH grant for endometriosis therapeutic

EndoCyclic Therapeutics has been awarded a National Institute of Health (NIH) Commercialization Readiness Pilot (CRP) Program grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD.

This funding will accelerate the commercialisation of ENDO-205, a non-hormonal, disease-modifying therapeutic designed to treat endometriosis.

The CRP grant provides late-stage development resources to propel promising therapies toward the clinic.

ENDO-205 employs a pH-sensitive peptide mechanism that selectively eliminates lesions at the site of the disease, while leaving healthy tissue untouched.

This targeted approach allows the drug to fully eliminate lesions across all subtypes of the disease while maintaining a good safety profile.

US$4.5m to Drive US launch of breast surgery platform

Medtech startup Plexāā has raised US$4.5m funding to support the US launch of BLOOM43 – the world’s first fully wearable medical device designed to help patients prepare for breast cancer surgery.

Complication rates in breast surgeries, which can include infection, skin necrosis and the need for additional surgeries, have been recorded as high as 30 per cent.

BLOOM43 utilises Supraphysiological Preconditioning – a new technique that preconditions the skin, causing the release of heat-shock proteins that cause vasodilation and increased blood flow to the area.

According to the company, the process has reduced wound healing complications in proof-of-concept clinical trials and the device has demonstrated substantial improvements in the patient experience and surgical readiness.

Further investment includes over US$1.6m in i4i grant funding from the National Institute for Health and Care Research (NIHR), and US$1.3m from Thena Capital, a London-based VC firm backed by the British Business Bank.

The company says the funding will also support future innovations.

Berry Fertility launches AI powered tool for patient communications

Berry Fertility, a comprehensive patient-management platform for IVF, IUI, embryo transfer and egg freezing, has launched its AI-powered Smart Compose tool for patient communications.

Smart Compose is designed to integrate into existing workflows and EMRs to support care teams without disrupting day-to-day operations.

It pulls relevant chart details, reviews patient messages and references history to create a message draft that clinical staff can review and tweak before responding to patients.

The tool, which is purpose-built for the unique needs of fertility clinics and care teams, enables decisions and clinical judgment to be human-led.

The agentic AI system uses a “human-in-the-loop” approach, enabling staff to remain in control and review, edit or discard drafts before they are sent to patients.

By drawing on vetted fertility content and a medication database developed by Berry Fertility, the tool is fully customisable to each clinic’s workflows.

To ensure the safeguarding of data, all data remain isolated to ensure workflows are not shared or used to improve any other system, and no AI models are trained on patient data.

Medical partnership launches femtech product for menstrual cramps

Spark Biomedical and Velentium Medical, partners in neuromodulation device development, have partnered to launch OhmBody.

OhmBody is a division of Spark Biomedical that is working to develop a wearable, non-invasive wellness product intended to help reduce cramps and unhealthy amounts of menstrual blood loss.

Spark Biomedical says that the product is also designed to provide support for other disruptive effects of your period like fatigue, gastric discomfort, and emotional fluctuations.

Seven Starling raises US$8m for mental health platform expansion

Seven Starling has raised US$8m in funding to accelerate the national US expansion of its maternal mental health platform.

Currently operating in 18 states, the company plans to expand to over 30 states by the end of 2026.

The expansion will increase access to specialised care for women experiencing mental health challenges during fertility, pregnancy, postpartum and early parenthood.

According to Seven Starling, the platform has seen 90 per cent clinical improvement in patients who complete the programme, showing significant reductions in depression symptoms.

The platform offers automated patient screening technology, one-click referrals and direct EMR integrations.

It also automates critical operational functions including insurance verification, personalised care team assignment and care co-ordination, and utilises AI for administrative workflows.

“We’ve built technology to solve the operational challenges that typically create friction in healthcare delivery,” said Sophia Richter, COO and co-founder of Seven Starling.

Axia Women’s Health launches AI mammograms

Axia Women’s Health will be offering an FDA-cleared AI technology with every mammogram.

The development aims to increase access to earlier and more accurate breast cancer detection.

The technology known as MammoScreen acts as a “second set of eyes” for radiologists providing a dual-read approach to every mammogram.

In retrospective studies, MammoScreen detected 38.5 per cent of screen detectable cancers two years before diagnosis.

Through a partnership with Onsite Women’s Health, MammoScreen is now available across the Axia Women’s Health network, with multiple imaging centers in Pennsylvania, New Jersey, and Indiana.

Each imaging center is located within or near existing Axia OB/GYN care centers, making it more convenient for women to receive the comprehensive care they need.